Bladder cancer trial aims to save organs without sacrificing survival

NCT ID NCT02710734

Completed Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to treat muscle-invasive bladder cancer by tailoring therapy based on each patient's tumor genetics. After initial chemotherapy, patients with a good response could avoid bladder removal and instead opt for active monitoring or less invasive treatments. The goal was to see if this personalized approach could keep cancer from spreading while preserving quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA OF THE BLADDER

Contacts and locations

Locations

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
Sidney kimmel Cancer Center

Philadelphia, Pennsylvania, 19107, United States
Washington Cancer Institute at MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.